Drug intelligence / Profile preview

Rimactal INH

Development stage: Unknown
Lead developer: Global Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Rimactal INH is a fixed-dose combination antibiotic therapy containing rifampicin and isoniazid, developed and marketed by Global Pharmaceuticals in Pakistan. It is indicated for the treatment and prevention of tuberculosis (TB) and other susceptible bacterial infections. Rifampicin, a rifamycin derivative, inhibits bacterial DNA-directed RNA polymerase, thereby blocking RNA synthesis. Isoniazid is a prodrug that, once activated by the bacterial enzyme KatG, inhibits the synthesis of mycolic acids, which are essential components of the mycobacterial cell wall. This dual-action approach targets both actively dividing and dormant *Mycobacterium tuberculosis* bacilli.

Brand names: Rimactal INH
Other names: rifampicin + isoniazid

Targets

rpoB (DNA-directed RNA polymerase subunit beta)InhA

Beyond the preview

Go deeper on Rimactal INH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rimactal INH.

Explore the full profile